@ARTICLE{
author={Mateos Maria-Victoria|,Szarejko Monika|,Bila Jelena S|0000-0003-2025-9653,Schjesvold Fredrik|,Spicka Ivan|,Maisnar Vladimir|,Jurczyszyn Artur|,Grudeva-Popova Zhanet|,Hajek Roman|,Usenko Hanna|,Thuresson Marcus|,Norin Stefan|,Jarefors Sara|,Richardson Paul|,Pour Ludek|},
year={2023},
title={Lighthouse: melflufen, daratumumab, and dexamethasone versus daratumumab in relapsed/refractory multiple myeloma refractory to an imid and a proteasome inhibitor or with ≥3 prior lines of therapy},
journal={CLINICAL LYMPHOMA MYELOMA & LEUKEMIA},
volume={23},
number={},
pages={S200-S201},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Kropff M|,Baylon H|,Spicka Ivan|,Hillengass J|,Roback T|,Salwender H|,Hajek Roman|,Liebisch P|,Boskovic Darinka V|,Goranov S|,Zerbib R|},
year={2009},
title={OPTIMUM Trial: Randomized Comparison of Thalidomide Versus Dexamethasone for Relapsed Myeloma},
journal={CLINICAL LYMPHOMA & MYELOMA},
volume={9},
number={},
pages={S64-S64},
document_type={Meeting Abstract},
}